Insights & Research

Evidence-based articles on GLP-1 microdosing, metabolic optimization, and precision protocols.

A school backpack and running shoes on a sunlit kitchen counter beside a glass of water and a plate of grilled chicken and greens

Adolescents 11 min readNewOctober 19, 2026

GLP-1 Medicines for Teenagers: What STEP TEENS and the Adolescent Trials Show About Weight, Doses and Side Effects

Semaglutide cut BMI by 16.1% in teenagers with obesity over 68 weeks. What STEP TEENS, the liraglutide trial and SURPASS-PEDS show about gallstones, mood, the 1.7 mg teen dose and stopping.

MicrodoseGLPs Research

Read Article

A hand drawing spirals in a notebook beside an injection pen and a brain model, representing GLP-1 research in Parkinson's disease

Brain HealthParkinson'sClinical Trials

Brain Health 10 min readOctober 16, 2026

GLP-1 Medicines and Parkinson's Disease: What LIXIPARK, Exenatide-PD3 and the Cohort Data Show

Lixisenatide slowed motor decline in a 156-person trial. The larger exenatide phase 3 trial found nothing. What the trials, the cohort data and the side effects show, and why no low dose has ever been tested.

MicrodoseGLPs Research

Read Article

An injection pen beside a measuring tape, a protein shake and a folded surgical follow-up chart, representing GLP-1 treatment after bariatric surgery

Weight RegainBariatric SurgeryClinical Trials

Weight Regain 10 min readOctober 15, 2026

GLP-1 Medicines After Bariatric Surgery: What the Trials Show About Weight Regain and Low Dose Use

Up to 40% of bariatric patients regain weight. In BARI-OPTIMISE, liraglutide cut a further 8.82% against 0.54% on placebo. How the GLP-1 drugs compare, how they stack up against revision surgery, and what nobody has tested at low doses.

MicrodoseGLPs Research

Read Article

An open notebook with a hand-drawn mood tracking grid, a pencil and a capped injection pen on a sunlit desk, representing mood monitoring on GLP-1 protocols

SafetyMental HealthRegulatory

Safety 10 min readOctober 14, 2026

GLP-1 Medicines and Suicidal Thoughts: What the FDA, EMA and Cohort Studies Found About Mood Risk

In January 2026 the FDA dropped the suicide warning from Wegovy, Zepbound and Saxenda after 91 trials showed no added risk. Here is what the trials, the EMA and the cohort studies found, and who the data still leave out.

MicrodoseGLPs Research

Read Article

A glass of lemon water beside a small dish of smooth stones and an injection pen on a pale countertop, representing hydration and kidney stone risk on GLP-1 protocols

Side EffectsKidney HealthSafety

Side Effects 10 min readOctober 13, 2026

GLP-1 Microdosing and Kidney Stones: Weight Loss, Urine Chemistry, and What the Cohort Data Shows

Obesity raises kidney stone risk, and stone formers losing weight on GLP-based therapy saw urine oxalate fall from 40 to 32 mg a day. Yet a VA study of 215,970 GLP-1 users flagged more stones. Here is how those findings fit together.

MicrodoseGLPs Research

Read Article

An anatomical model of the intestines on white linen beside a glass of water and a sage green cloth, representing the gut and GLP-1 bowel side effects

Side EffectsGut HealthSafety

Side Effects 10 min readOctober 12, 2026

GLP-1 Protocols and Bowel Obstruction: What the Ileus Warning Means and Which Symptoms Matter

Ileus and intestinal obstruction are now on the Ozempic and Wegovy labels. Yet across 121,254 GLP-1 users in three Nordic countries, obstruction was no more common than on SGLT2 inhibitors. Here is how the signal and the data fit together.

MicrodoseGLPs Research

Read Article

An injection pen and a blister pack of tablets on a sage green cloth beside a glass of water and an anatomical kidney model, representing a weekly GLP-1 combined with a daily SGLT2 inhibitor

CombinationsKidneyMetabolic Health

Combinations 10 min readOctober 11, 2026

SGLT2 Inhibitors and GLP-1s Together: What the Combination Trials Show About Weight, Blood Sugar and Kidneys

Adding semaglutide to an SGLT-2 inhibitor took off a further 3.81 kg in SUSTAIN 9. Whether the pairing protects the kidneys or heart better than one drug alone is a different, less settled question.

MicrodoseGLPs Research

Read Article

A health insurance card, a pharmacy receipt and a prescription bottle beside an injection pen and a small calculator on a linen tabletop, representing the cost and coverage of GLP-1 medicines

CostInsuranceAccess

Cost 10 min readOctober 10, 2026

Is Microdosing GLP-1 Covered by Insurance? What Plans Actually Pay For in 2026

Only 19% of firms with 200 or more workers cover GLP-1s for weight loss, and the labels draw a line between starting and maintenance doses. What employer plans, Medicare's $50 GLP-1 Bridge and cash prices mean for low-dose protocols.

MicrodoseGLPs Research

Read Article

An open notebook with a daily check-in chart, a calendar with crossed-off days, a cup of tea and an injection pen on a wooden table, representing research on GLP-1 medicines and substance use

AddictionBrain HealthResearch

Addiction 11 min readOctober 9, 2026

Can GLP-1 Medicines Curb Opioid and Cannabis Use? What the Addiction Research Shows

In 524,817 US veterans, starting a GLP-1 was linked to fewer new opioid and cannabis use disorders. What the cohorts, overdose data and the first human trials show, and why the evidence is still early.

MicrodoseGLPs Research

Read Article

A glucose meter showing a normal fasting reading beside a lancing device, a notepad and a bowl of lentils, representing prediabetes testing and GLP-1 research

Blood SugarClinical TrialsMetabolic Health

Blood Sugar 10 min readOctober 8, 2026

GLP-1 Medicines and Prediabetes: What the Trials Show About Getting Blood Sugar Back to Normal

In SURMOUNT-1, 1.3% of people with prediabetes on tirzepatide developed type 2 diabetes over 176 weeks, against 13.3% on placebo. What the STEP, SURMOUNT-1 and SCALE trials show, what happens after stopping, and why microdose protocols are still untested.

MicrodoseGLPs Research

Read Article

An anatomical model of the human brain, representing research on GLP-1 medicines, Alzheimer's disease, and dementia risk

Brain HealthClinical TrialsLongevity

Brain Health 11 min readOctober 7, 2026

Can GLP-1 Medicines Lower Dementia Risk? What the EVOKE Trials Changed

Health record studies linked semaglutide with 40 to 70 percent fewer Alzheimer's diagnoses. Then the phase 3 EVOKE trials gave oral semaglutide to 3,808 people with early Alzheimer's and found no slowing of decline. What each line of evidence shows, which dementia risk factors GLP-1s move, and why microdosing has no brain data.

MicrodoseGLPs Research

Read Article

A clear bottle of water standing on a dark table against bright window blinds, representing hydration and dizziness during GLP-1 treatment

Side EffectsBlood PressureHydration

Side Effects 10 min readNewOctober 6, 2026

Dizziness on a GLP-1: Why Semaglutide and Tirzepatide Can Make You Lightheaded

Dizziness was reported by 8 percent of adults on semaglutide 2.4 mg versus 4 percent on placebo. Why lower food and fluid intake, GI losses, and a 6 to 7 mmHg fall in systolic pressure cause head rushes on standing, who is most at risk, and which symptoms need a prescriber.

MicrodoseGLPs Research

Read Article

An empty bed with pale linen in a quiet room lit by early morning light, representing intimacy and sexual health during GLP-1 treatment

HormonesMen's HealthWomen's Health

Hormones 11 min readOctober 5, 2026

GLP-1s and Libido: What the Research Says About Sex Drive, Erections, and Hormones

Low libido is not a listed side effect of semaglutide or tirzepatide, and weight loss helped 31 percent of men with obesity regain normal erectile function in a two-year trial. What the 2024 semaglutide ED database study really shows, how testosterone responds, and why desire can dip during dose escalation.

MicrodoseGLPs Research

Read Article

A small bowl of soup on a plain table, representing the small, plain meals that tend to sit better during GLP-1 nausea

Side EffectsGut HealthDosing

Side Effects 11 min readOctober 4, 2026

GLP-1 Nausea and Vomiting: Why It Happens, Which Days Are Worst, and What Helps

Nausea is the most common side effect of semaglutide and tirzepatide, reported by up to 44 percent of trial participants and usually worst one to three days after each injection. What drives it, how long an episode lasts, and the eating changes that make the biggest difference.

MicrodoseGLPs Research

Read Article

A white ceramic teapot and a cup of warm tea on a wooden tray, representing gentle fluids during GLP-1 digestive side effects

Side EffectsGut HealthHydration

Side Effects 11 min readOctober 3, 2026

GLP-1 Diarrhea and Loose Stools: Why It Happens, How Long It Lasts, and What Helps

Up to a third of people in the big semaglutide and tirzepatide trials reported diarrhea, usually in bouts of about three days after a dose step. Why a drug that slows the stomach can loosen stools, the protein bar ingredients that make it worse, and how to rehydrate properly.

MicrodoseGLPs Research

Read Article

Bamboo toothbrushes in a glass jar beside a sprig of eucalyptus, representing daily oral care on a GLP-1 protocol

Side EffectsOral HealthHydration

Side Effects 10 min readOctober 2, 2026

GLP-1 Dry Mouth, Bad Breath, and Dental Health: What Changes and What Helps

Less drinking, fewer meals, and vomiting during escalation all cut saliva, the mouth's acid buffer. Where GLP-1 bad breath really comes from, how ketone breath differs, why enamel erosion follows vomiting, and the cheap habits that protect teeth.

MicrodoseGLPs Research

Read Article

A cup of tea on a wooden coaster beside two biscuits, representing small, gentle meals on a GLP-1 protocol

Side EffectsDigestionGut Health

Side Effects 10 min readOctober 1, 2026

GLP-1 Sulfur Burps, Bloating, and Gas: Why They Happen and What the Data Shows

Belching shows up in 7 percent of people on semaglutide 2.4 mg and under 1 percent on placebo. How slowed gastric emptying and hydrogen sulfide produce the rotten egg taste, why symptoms cluster after dose increases, which foods matter, and the bloating red flags that need a doctor.

MicrodoseGLPs Research

Read Article

An open monthly planner and a cup of coffee, representing tracking a menstrual cycle alongside a GLP-1 protocol

Women's HealthMenstrual CycleAppetite

Women's Health 10 min readNewSeptember 30, 2026

GLP-1s and the Menstrual Cycle: Luteal Hunger, Scale Swings, Birth Control, and Iron

Luteal phase eating runs 90 to 500 kcal a day higher, and premenstrual water can hide a month of progress on the scale. Why tirzepatide carries a 4 week birth control warning that semaglutide does not, the iron numbers menstruating women should know, and why cycle-synced dosing is still untested.

MicrodoseGLPs Research

Read Article

Blister packs of white tablets, representing metformin taken alongside a GLP-1 protocol

Metabolic HealthMetforminCombinations

Metabolic Health 10 min readNewSeptember 29, 2026

Metformin and GLP-1s Together: What the Trials Show About Weight, Blood Sugar, B12, and Side Effects

Metformin alone moved weight about 2 percent in the Diabetes Prevention Program. What SURPASS-2 showed when semaglutide or tirzepatide was added on top, why the stomach side effects can stack, the B12 and kidney checks that matter, and what is still untested at microdose levels.

MicrodoseGLPs Research

Read Article

A passenger jet climbing through a clear blue sky, representing travel and flying while on a GLP-1 protocol

ProtocolsStorageTravel

Protocols 10 min readSeptember 28, 2026

Travelling on a GLP-1: Flying With Pens and Vials, Heat, Time Zones, and Dose Day Rules

How long each pen can live out of the fridge, why GLP-1s never go in the hold, how a parked car passes the 86 F limit in ten minutes, the 48 and 72 hour rules for moving a dose day across time zones, and why a stomach bug abroad is the one travel risk worth planning for.

MicrodoseGLPs Research

Read Article

A snow covered pine forest beside a frozen lake in mist, representing the cold sensitivity many people notice during GLP-1 weight loss

Side EffectsMetabolismThermoregulation

Side Effects 10 min readNewSeptember 27, 2026

Why Do You Feel Cold on a GLP-1? Body Temperature, Metabolic Adaptation, and What Microdosing Changes

Cold hands and a higher thermostat are common complaints on semaglutide and tirzepatide, yet cold intolerance is not a listed side effect. How a 24 percent drop in food intake, metabolic adaptation, lost insulation, and low iron or thyroid output explain it, and when feeling cold is worth a blood test.

MicrodoseGLPs Research

Read Article

A wide open landscape under a clear sky, representing easier breathing after quitting smoking

CravingsBrain RewardWeight Management

Cravings 10 min readSeptember 26, 2026

GLP-1 Microdosing and Quitting Smoking: Nicotine Cravings, Post Quit Weight Gain, and What the Trials Show

Quitters gain an average of 4.67 kg in their first smoke free year, and fear of that gain keeps many people smoking. What the exenatide and dulaglutide trials found on quit rates and weight, how GLP-1 signalling acts on nicotine reward in animal studies, and why the heart benefit of quitting still outweighs the weight.

MicrodoseGLPs Research

Read Article

A man crouching on a city pavement to tie his running shoe before a walk, representing the everyday movement that makes up NEAT

MovementMetabolismBody Recomposition

Movement 10 min readSeptember 25, 2026

NEAT and Daily Steps on a GLP-1 Microdose: The Energy You Stop Burning Without Noticing

NEAT makes up 15 to 30 percent of daily energy burn, and it tends to slide when you eat less. How much a drop from 8,000 to 5,000 steps costs, what the S-LiTE trial found when exercise was added to liraglutide, the step count where the mortality data levels off, and why ten minutes of walking after your biggest meal is worth keeping.

MicrodoseGLPs Research

Read Article

A person sitting quietly at the end of a wooden jetty on a still mountain lake, representing the calm that returns once early GLP-1 headaches settle

Side EffectsHydrationBrain

Side Effects 10 min readSeptember 24, 2026

Headaches on a GLP-1 Microdose: Why They Happen, How Long They Last, and What the Trials Show

Headache hit 15.2 percent of people on semaglutide in STEP 1, but 10.4 percent on placebo too. Why most GLP-1 headaches trace back to less water, less salt, longer gaps between meals, and the coffee you quietly stopped drinking, when they appear and fade, what the IIH:Pressure trial and a 2025 migraine pilot suggest about brain pressure, and which headaches are warning signs.

MicrodoseGLPs Research

Read Article

Mountain peaks above a flat sea of cloud at dusk, representing the level stretch that follows a period of steady weight loss on a GLP-1

ProtocolsWeight LossMetabolism

Protocols 11 min readNewSeptember 23, 2026

Weight Loss Plateaus on a GLP-1 Microdose: Why the Scale Stops and What the Trials Say About It

Every GLP-1 trial curve flattens while people are still taking the drug. Why appetite feedback, at roughly 100 extra calories a day per kilogram lost, does more to stop weight loss than a slowing metabolism, how to tell a real plateau from a month of scale noise, what the O'Neil 2018 dose finding trial says about where lower doses land, and why stopping at a plateau usually means regain.

MicrodoseGLPs Research

Read Article

A rack of dumbbells in a quiet gym, representing the resistance training that creatine supports during weight loss on a GLP-1

Body RecompositionSupplementsMuscle

Body Recomposition 12 min readNewSeptember 22, 2026

Creatine and GLP-1 Microdosing: The Supplement With the Best Case for Protecting Lean Mass While the Scale Falls

Thirty nine percent of the weight lost on semaglutide in the STEP 1 DEXA substudy was lean mass. Creatine monohydrate at 3 to 5 grams a day is the best studied supplement for keeping and building lean mass alongside resistance training. What the meta-analyses in adults over 50 show, why a loading phase is a bad idea on a GLP-1, why creatine will move your creatinine and estimated GFR without touching your kidneys, and why women and people eating less meat have the most to gain.

MicrodoseGLPs Research

Read Article

A person sitting quietly in the early morning light, representing the stress response that shapes appetite and eating on a GLP-1

Metabolic HealthMental HealthHormones

Metabolic Health 12 min readNewSeptember 20, 2026

Cortisol, Stress Eating, and GLP-1 Microdosing: What Happens to the Stress Response When Appetite Signalling Changes

Stress eating is a cortisol loop: the hormone raises the appeal of energy dense food and the food turns the stress response down. GLP-1 receptors sit in the brain regions that launch that response and in the reward circuit that closes the loop. What the human and animal data say about GLP-1s and the HPA axis, why the STEP 5 control of eating results matter, and why the dose ramp, the deficit, sleep, and exercise intensity all move cortisol.

MicrodoseGLPs Research

Read Article

A cup of coffee on a wooden table in morning light, representing the daily caffeine habit that changes for many people on a GLP-1

LifestyleSide EffectsNutrition

Lifestyle 11 min readNewSeptember 19, 2026

Coffee and Caffeine on a GLP-1 Microdose: Absorption, Nausea, Withdrawal Headaches, and Heart Rate

Caffeine is not on the interaction list, yet coffee feels different on a GLP-1. Slowed gastric emptying delays the caffeine peak by up to an hour, coffee on an empty stomach becomes a nausea trigger, an accidental drop in intake produces withdrawal headaches that get blamed on the drug, and the modest heart rate rise adds to caffeine's own. What the prescribing information reports, and how to time it.

MicrodoseGLPs Research

Read Article

A person resting in bed in soft daylight, representing the low energy that many people report in the first weeks on a GLP-1

Side EffectsEnergyNutrition

Side Effects 11 min readNewSeptember 18, 2026

Why Do You Feel Tired on a GLP-1 Microdose? Fatigue, Energy Intake, and What the Trials Report

Fatigue was reported by about 11 percent of adults on semaglutide 2.4 mg and 5 to 7 percent on tirzepatide in the obesity trials. Most of it traces to a 20 to 25 percent fall in energy intake, depleted glycogen, and low fluid and sodium rather than a direct drug effect. Why it clusters around dose increases, what energy availability means, and what to check when the tiredness does not lift.

MicrodoseGLPs Research

Read Article

Clinical laboratory analyzers processing blood samples, representing the glucose measurements behind the hypoglycemia data in this article

Blood SugarSafetyMechanism

Blood Sugar 11 min readNewSeptember 17, 2026

Can a GLP-1 Microdose Cause Low Blood Sugar? What the Trials Show About Hypoglycemia Without Diabetes

GLP-1 receptor agonists stimulate insulin only when glucose is elevated, which is why clinically significant hypoglycemia was reported in under 1 percent of participants without diabetes in the semaglutide and tirzepatide obesity trials. Where the real risk comes from, why the shaky feeling on a GLP-1 is usually not low glucose, and what the data say about reactive hypoglycemia after meals.

MicrodoseGLPs Research

Read Article

Close up of an analogue clock face, representing the timing and half-life questions behind a missed GLP-1 dose

Missed DosePharmacokineticsProtocol

Missed Dose 11 min readNewSeptember 16, 2026

Missed a GLP-1 Microdose? What Half-Life and Steady State Mean for the Next Injection

Semaglutide has a half-life of about 7 days and tirzepatide about 5, which sets how fast the drugs build up, how far a missed dose lets the level fall, and how long the labels give you to catch up. What the prescribing information says to do, why re-escalation is advised after two missed weeks, and what a split schedule does to the peak and trough.

MicrodoseGLPs Research

Read Article

Gloved hand filling a small glass vial from a dropper in a laboratory, representing the investigational triple agonist retatrutide discussed in this article

RetatrutideTriple AgonistResearch

Retatrutide 12 min readNewSeptember 15, 2026

Retatrutide and Microdosing: What the Triple Agonist Trials Show at the Low End of the Dose Curve

Retatrutide activates GLP-1, GIP, and glucagon receptors and produced about 25 percent weight loss over 80 weeks in TRIUMPH-1, with liver fat cut by more than 80 percent at the higher doses. What the 1 mg and 4 mg arms showed, why starting dose changed side effects in a controlled test, and what the glucagon component means for heart rate.

MicrodoseGLPs Research

Read Article

Close up of white tablets spilling from a bottle, representing the oral GLP-1 medicines discussed in this article

Oral GLP-1OrforglipronResearch

Oral GLP-1 12 min readNewSeptember 14, 2026

Oral GLP-1s and Microdosing: What Orforglipron and the Semaglutide Pill Change for Low Dose Protocols

Two GLP-1 tablets reached the US market in 2026: the semaglutide pill and orforglipron, the first small molecule in the class. What the ATTAIN and OASIS trials showed, why a pill needs 70 times more semaglutide than an injection, and what fixed tablet strengths and daily absorption swings mean for a low dose approach.

MicrodoseGLPs Research

Read Article

Researcher working at a laboratory bench with sample vials, representing the amylin analog and combination peptide trials discussed in this article

AmylinPeptide PipelineResearch

Amylin 12 min readNewSeptember 13, 2026

Amylin Analogs and GLP-1 Microdosing: What Cagrilintide, CagriSema and Amycretin Add to the Picture

Amylin is the hormone released alongside insulin at every meal. What cagrilintide, CagriSema, petrelintide, eloralintide and amycretin have shown in trials, why a second pathway beats a higher dose of the first, and what the front-loaded dose curves mean for low dose thinking.

MicrodoseGLPs Research

Read Article

Bowls of fresh fruit and yoghurt on a wooden table, representing the shift toward lighter and less energy-dense foods that many people describe on a GLP-1 protocol

Taste ChangesAppetiteSide Effects

Taste Changes 11 min readNewSeptember 12, 2026

GLP-1 Microdosing and Taste Changes: Why Sweet Foods Get Sweeter and Favourites Lose Their Pull

GLP-1 receptors sit inside taste buds as well as in the brain. What the trials recorded, what the feeding studies measured, why early aversions fade while preference shifts persist, and which taste complaints have a different cause.

MicrodoseGLPs Research

Read Article

A small bowl of soup on a plain table, representing the smaller and lighter meals that sit more comfortably during early GLP-1 dosing

Acid RefluxDigestive HealthSide Effects

Acid Reflux 11 min readNewSeptember 11, 2026

GLP-1 Microdosing and Acid Reflux: Why Heartburn Peaks Early and Then Usually Fades

Delayed gastric emptying pushes reflux up in the first weeks while weight loss pulls it down over months. The trial numbers, the mechanism, the timing, and what a gentler ramp is and is not known to do.

MicrodoseGLPs Research

Read Article

Laboratory glassware under cool light, representing the blood chemistry panel that reports serum urate

Uric AcidBiomarkersSafety

Uric Acid 11 min readNewSeptember 9, 2026

GLP-1 Microdosing and Uric Acid: Why Gout Flares Cluster Early in Rapid Weight Loss

Serum urate rises before it falls during rapid weight loss, and gout flares cluster in the first three months. The ketone mechanism behind it, and what a slower rate of change is and is not known to do.

MicrodoseGLPs Research

Read Article

A pair of spectacles resting on an open book, representing vision and eye health

Eye HealthSafetyMonitoring

Eye Health 12 min readNewSeptember 8, 2026

GLP-1 Protocols and Eye Health: What the Retinopathy Signal and the NAION Reports Actually Say

SUSTAIN-6 found more diabetic retinopathy complications on semaglutide, and European regulators added NAION to the label in 2025. Two separate signals with different mechanisms, and what the rate of glycaemic change has to do with both.

MicrodoseGLPs Research

Read Article

Runners moving along a road at pace, representing aerobic training capacity

PerformanceTrainingBody Composition

Performance 12 min readNewSeptember 7, 2026

Aerobic Capacity on a GLP-1 Protocol: Why VO2 Max Rises Without the Engine Getting Bigger

Relative VO2 max climbs on a GLP-1 protocol because body weight sits in the denominator. Absolute aerobic capacity is a different number, and it behaves differently. What the trial data shows about walking distance, fuelling, heart rate zones and lean mass.

MicrodoseGLPs Research

Read Article

A stethoscope resting on a flat surface, representing clinical measurement of heart rate

CardiovascularMonitoringTrial Data

Cardiovascular 12 min readNewSeptember 6, 2026

Resting Heart Rate on GLP-1 Protocols: Why the Pulse Rises While the Weight Comes Off

GLP-1 medications raise resting heart rate by roughly 1 to 4 beats per minute, and they do it while weight loss is pushing the pulse in the opposite direction. What the cardiovascular outcome trials found, and what the number does not tell you.

MicrodoseGLPs Research

Read Article

A bowl of leafy greens, grains and vegetables on a table, representing dietary fiber intake

DigestionSide EffectsNutrition

Digestion 11 min readNewSeptember 4, 2026

Constipation on GLP-1 Protocols: Slowed Transit, Shrinking Meals and Why the Fiber Advice Often Backfires

Constipation affected about one in four participants at the full semaglutide dose in STEP 1. The mechanism is mostly not a brake on the colon, and understanding which part of the digestive tract actually slowed changes what to do about it.

MicrodoseGLPs Research

Read Article

A pharmacist working at a laboratory bench surrounded by reagent bottles, representing compounding pharmacy preparation

CompoundingDosingSafety

Compounding 11 min readNewSeptember 2, 2026

Compounded Vials vs Brand Pens: Concentration, Units and the Arithmetic Behind GLP-1 Dosing Errors

A unit is a volume and a milligram is a quantity, and the gap between them is where most reported GLP-1 dosing errors live. What concentration actually determines, why small doses are the most error-sensitive, and what changed after the shortage ended.

MicrodoseGLPs Research

Read Article

Glucose monitoring equipment on a table, representing continuous glucose tracking

CGMGlucoseTracking

CGM 12 min readNewSeptember 1, 2026

What a CGM Shows on a Microdose GLP-1 Protocol: Post-Meal Peaks, Time in Range and Glycemic Variability

Continuous glucose monitors are now sold over the counter, and the first thing a GLP-1 changes on the trace is the shape of the post-meal curve rather than the fasting number. How to read the pattern, which metrics mean something, and where the data runs out.

MicrodoseGLPs Research

Read Article

A surgical team working in an operating theatre, representing perioperative planning

SurgeryAnesthesiaSafety

Surgery 12 min readNewAugust 29, 2026

Surgery, Anesthesia and GLP-1 Protocols: Whether to Hold the Dose and What the Fasting Guidance Changed

The advice to stop a GLP-1 for a week before surgery was superseded in 2024 by individualized risk assessment and a 24 hour clear liquid diet. What changed, why gastric emptying matters at induction, and what to tell the anesthesia team.

MicrodoseGLPs Research

Read Article

A laboratory scientist handling blood samples, representing pancreatic enzyme testing

PancreasLab WorkSafety

Pancreas 12 min readNewAugust 28, 2026

Pancreatitis, Lipase and GLP-1 Protocols: What the Enzyme Numbers Mean and When Pain Is an Emergency

Lipase rises about a quarter above baseline on GLP-1 therapy without anything being wrong, while the diagnostic threshold sits at three times normal. Where the warning comes from, what the trial rates show, and how to tell ordinary nausea from the pain that needs a hospital.

MicrodoseGLPs Research

Read Article

A clinical setting with laboratory equipment, representing thyroid function monitoring

ThyroidDrug InteractionsMonitoring

Thyroid 12 min readNewAugust 27, 2026

The Thyroid and GLP-1 Protocols: Levothyroxine Absorption, Drifting TSH and the C-Cell Warning

Tirzepatide raises total levothyroxine exposure by roughly a third while lowering its peak, weight loss pulls TSH down on its own, and the boxed warning everyone quotes comes from rodents. Three separate thyroid questions, separated.

MicrodoseGLPs Research

Read Article

A woman sitting in soft daylight, representing reproductive planning during metabolic treatment

FertilityContraceptionWomen's Health

Fertility 12 min readNewAugust 25, 2026

Fertility, Birth Control and GLP-1 Protocols: The Two Mechanisms Behind Ozempic Babies

Tirzepatide cuts peak oral contraceptive concentrations by more than half, and weight loss restores ovulation in a large share of women who were not cycling. Two separate mechanisms, two separate plans, and where a lower dose sits on each.

MicrodoseGLPs Research

Read Article

An empty bed with pale linen in a quiet room lit by early morning light

Sleep ApneaAirwayClinical Data

Sleep Apnea 12 min readAugust 24, 2026

Sleep Apnea and GLP-1 Protocols: What the Airway Data Actually Shows

Tirzepatide cut the apnea-hypopnea index by 25 to 29 events per hour in SURMOUNT-OSA, and the effect ran almost entirely through weight loss. Why tongue fat matters more than neck size, and where a lower dose sits on that curve.

MicrodoseGLPs Research

Read Article

Water being poured from a jug into a clear glass on a pale table

HydrationElectrolytesSide Effects

Hydration 12 min readNewAugust 23, 2026

Hydration and Electrolytes: Why Fluid Intake Falls Along With Food Volume

Nobody decides to drink less water on a GLP-1 protocol. They decide to eat less, and the water leaves with the food. Where the missing litre goes, what happens to sodium and potassium, and when fluid loss is worth a phone call.

MicrodoseGLPs Research

Read Article

An overhead view of whole foods including greens, eggs, nuts and fish arranged on a table

NutritionLab MonitoringMicronutrients

Nutrition 12 min readNewAugust 22, 2026

Iron, B12, and Vitamin D: What Happens to Nutrient Status When Food Volume Falls

A GLP-1 medication does not take iron out of your blood. It takes food off your plate, and iron happens to be in the food. Which nutrients run short first, how long before a blood draw shows it, and what belongs on the panel.

MicrodoseGLPs Research

Read Article

A laboratory technician measuring a small liquid volume with a precision pipette

ProtocolDose AccuracyStorage

Protocol 13 min readNewAugust 21, 2026

Injection Sites, Dose Accuracy, and Cold Chain: The Handling Variables That Change What You Actually Receive

Which site you inject barely matters, and the labels say so. What does matter is the arithmetic between the vial and the syringe, the back wall of your refrigerator, and the patch of skin that has taken every injection since March.

MicrodoseGLPs Research

Read Article

A plated meal of salmon and vegetables on a dark table

MechanismDigestive HealthDrug Interactions

Mechanism 12 min readAugust 20, 2026

Delayed Gastric Emptying: The Mechanism Behind Both the Fullness and the Nausea

One physiological change produces the satiety, the queasiness, the flatter glucose curve, and the question your anesthesiologist now asks. How large the delay is, why it fades over weeks, and what it does to the absorption of your other medications.

MicrodoseGLPs Research

Read Article

A prepared bowl of vegetables, grains and olive oil on a wooden table

SafetyDigestive HealthRate of Loss

Safety 12 min readNewAugust 19, 2026

The Gallbladder Question: Why Pace of Weight Loss Drives Gallstone Risk

Pooled trial data show a modest rise in gallbladder events on GLP-1 medications, and most of the mechanism belongs to rapid weight loss rather than the molecule. How supersaturated bile and slowed emptying stack, and what a gentler protocol is expected to change.

MicrodoseGLPs Research

Read Article

Legs in running shoes climbing a set of concrete steps, representing daily incidental movement

MetabolismBody CompositionMaintenance

Metabolism 12 min readNewAugust 18, 2026

The Slowdown Underneath: Metabolic Adaptation on a GLP-1 Protocol

Resting metabolic rate falls during any weight loss, and part of that fall runs deeper than body composition predicts. What drives adaptive thermogenesis, why step counts drift down on their own, and what a gentler protocol is expected to change.

MicrodoseGLPs Research

Read Article

Blood pressure cuff and monitor on a pale surface, representing cardiovascular measurement

CardiovascularBlood PressureMonitoring

Cardiovascular 11 min readNewAugust 17, 2026

Pressure Down, Pulse Up: What GLP-1 Microdosing Does to Blood Pressure

These drugs lower systolic pressure by a modest, fairly consistent amount, most of it riding on weight loss, while nudging resting heart rate slightly upward. Why baseline pressure predicts the response, and what a slower protocol changes.

MicrodoseGLPs Research

Read Article

Comb and hair care tools on a pale surface, representing hair density and shedding

Hair HealthSide EffectsRate of Loss

Hair Health 11 min readAugust 15, 2026

The Three Month Lag: GLP-1 Weight Loss, Hair Shedding, and Telogen Effluvium

Shedding starts about a season after the thing that caused it, which is why most people blame the wrong week. What triggers it, why rate of loss predicts it better than dose does, and what a slower protocol changes.

MicrodoseGLPs Research

Read Article

Clinical laboratory with automated analyzers, where lipid panel bloodwork is processed

Lipid PanelApoBBloodwork

Lipid Panel 10 min readNewAugust 11, 2026

Triglycerides Move First: GLP-1 Microdosing and the Lipid Panel

Triglycerides fall hard while LDL barely budges, and ApoB tells a story neither one does. What actually changes across the panel, why the standard test hides particle count, and what a smaller dose likely does differently.

MicrodoseGLPs Research

Read Article

Water being poured into a clear glass, representing hydration and kidney perfusion

Kidney FunctioneGFRBloodwork

Kidney Function 10 min readAugust 10, 2026

The Number That Drops Before It Rises: GLP-1 Microdosing and Kidney Function

eGFR often falls in the first few months and then outperforms the untreated trajectory for years. What the early dip actually is, why albuminuria is the more useful number, and where dehydration becomes the real risk.

MicrodoseGLPs Research

Read Article

Loaded barbell resting on a gym floor, representing the mechanical loading that maintains bone

Bone HealthDXABody Composition

Bone Health 10 min readAugust 5, 2026

The Skeleton Loses Weight Too: GLP-1 Microdosing and Bone Density

About one percent of everything you lose comes off the skeleton, and unlike fat it does not come back. Here is what DXA data shows about bone during weight loss, why the femoral neck takes the worst of it, and how pace changes the outcome.

MicrodoseGLPs Research

Read Article

Overhead view of runners spread across a track, representing movement without joint pain

Joint HealthOsteoarthritisKnee Load

Joint Health 9 min readJuly 30, 2026

Four Pounds Per Step: GLP-1 Microdosing and Aching Joints

Every pound you carry lands on the knee about four times over. Here is what the STEP 9 trial found about GLP-1s and knee osteoarthritis, and why a gentler dose held longer may serve a joint better than a fast one.

MicrodoseGLPs Research

Read Article

Embers of a low fire representing chronic low-grade inflammation

Metabolic HealthInflammationhs-CRP

Metabolic Health 9 min readNewJuly 27, 2026

The Quiet Fire: How GLP-1 Microdosing Cools Chronic Inflammation

Chronic low-grade inflammation runs under most metabolic disease, and you cannot feel it. Here is what the trials found about GLP-1s and markers like hs-CRP, and why a gentler dose may capture much of the benefit.

MicrodoseGLPs Research

Read Article

A woman in calm morning light, representing steady metabolic health with PCOS

Women's HealthPCOSInsulin Resistance

Women's Health 9 min readJuly 24, 2026

PCOS and GLP-1 Microdosing: Loosening the Insulin Knot Without the Crash

For most women with PCOS, insulin sits at the center of the tangle. Here is how GLP-1 medications ease that pressure, and why a smaller dose can fit a lifelong condition better than a sprint.

MicrodoseGLPs Research

Read Article

A quiet, softly lit kitchen at dusk representing a calmer relationship with food

Appetite & BrainFood NoiseMicrodosing

Appetite & Brain 8 min readJuly 23, 2026

Food Noise, Explained: How Microdosing GLP-1s Quiet the Chatter Around Eating

It is the running commentary about what to eat next, looping even when you are full. Here is what food noise actually is, why GLP-1s turn the volume down, and where a smaller dose fits.

MicrodoseGLPs Research

Read Article

A man in soft morning light after training, representing men's metabolic and hormonal health

Men's HealthTestosteroneMicrodosing

Men's Health 9 min readJuly 22, 2026

Testosterone and the Weight Question: What Microdosing GLP-1s Do to Men's Hormones

For many men, a low testosterone reading is a weight problem wearing a hormone costume. Here is how GLP-1 driven fat loss lets the hormone recover, why muscle protection decides the outcome, and where a gentler dose fits.

MicrodoseGLPs Research

Read Article

Soft morning light over a glass of water and fresh food, representing metabolic and liver health

Metabolic HealthFatty LiverMicrodosing

Metabolic Health 9 min readJuly 21, 2026

The Liver Connection: How Microdosing GLP-1s May Ease Fatty Liver

The liver is often the first place fat leaves on a GLP-1, and it leaves faster than the scale suggests. Here is why the organ responds first, what the trials show, and where a gentler dose changes the picture.

MicrodoseGLPs Research

Read Article

A simple plate of food in soft light, representing appetite and hunger hormone regulation

Appetite ScienceGhrelin & LeptinMicrodosing

Appetite Science 9 min readJuly 19, 2026

Ghrelin, Leptin, and the Appetite Reset: How Microdosing GLP-1s Quiets the Hunger Hormones

The food noise goes quiet because two hormones change how loudly they speak. Here is what ghrelin and leptin actually do on a GLP-1, why hunger rebounds after stopping, and where a gentler dose changes the picture.

MicrodoseGLPs Research

Read Article

Soft natural light on a woman's face, representing skin and facial volume during GLP-1 weight loss

Skin & AestheticsOzempic FaceMicrodosing

Skin & Aesthetics 9 min readJuly 17, 2026

Ozempic Face: Why Fast Weight Loss Ages the Skin, and How Microdosing Softens the Landing

The hollow, deflated look after rapid GLP-1 weight loss is not a skin disease. It is a pacing problem. Here is what is actually happening in facial tissue, and where a smaller dose changes the picture.

MicrodoseGLPs Research

Read Article

A single glass of wine left untouched, representing reduced desire to drink on GLP-1 medication

Reward & CravingsAlcoholMicrodosing

Reward & Cravings 9 min readJuly 16, 2026

Why GLP-1 Microdosing Quiets the Urge to Drink, Not Just to Eat

People on GLP-1 medications keep reporting the same surprise: they want less alcohol. Here is what the research shows, why the reward wiring overlaps, and where a smaller dose fits in.

MicrodoseGLPs Research

Read Article

Person in a relaxed wellness pose representing GLP-1 maintenance microdosing

Weight ManagementMaintenanceMicrodosing

Weight Management 9 min readNewJuly 9, 2026

Microdosing GLP-1 for Maintenance: Keeping Results Without Full Doses

Stop the medication and most of the weight comes back. Stay on a full dose forever and the cost and side effects mount. Microdosing is the quiet third path — the smallest amount that holds the line once the hard part is done.

MicrodoseGLPs Research

Read Article

Weight rack in a dimly lit gym representing muscle retention during GLP-1 weight loss

Body CompositionMuscle RetentionMicrodosing

Body Composition 8 min readJuly 8, 2026

Why GLP-1 Users Lose Muscle, and How Microdosing Changes the Equation

The scale keeps moving. Underneath the number, a quieter trade is happening in tissue you cannot see. Here is what the trials actually found, and where a smaller dose fits in.

MicrodoseGLPs Research

Read Article

Clock representing peptide timing — morning, pre workout, or night

PeptidesProtocol TimingGrowth Hormone

Peptides 9 min readJuly 7, 2026

Peptide Timing: Morning, Pre Workout, or Night?

Timing is the cheapest variable in any peptide protocol. A class-by-class guide to when growth hormone secretagogues, healing peptides, and GLP-1 agonists actually work best — and why insulin, not the clock, is the real gatekeeper.

MicrodoseGLPs Research

Read Article

Medical imaging representing visceral vs subcutaneous fat targeting by GLP-1 therapy

Clinical GuideFat MetabolismGLP-1

Clinical Guide 9 min readJuly 6, 2026

Visceral Fat vs. Subcutaneous Fat: Which One GLP-1 Targets First

Not all fat is the same, and GLP-1 medicines do not treat it as if it were. Why visceral and liver fat leave first and fastest, and what that means for reading your own progress.

MicrodoseGLPs Research

Read Article

Medication and protocol representing a gentle GLP-1 microdosing titration ramp

Clinical GuideSide EffectsTitration

Clinical Guide 8 min readJuly 3, 2026

The Gentle Ramp: How a Microdosing Protocol Reduces GLP-1 Side Effects

Nausea is not the price of the medicine. It is the price of the climb. Slow the climb, and the story changes.

MicrodoseGLPs Research

Read Article

Microscopic cellular view representing insulin sensitivity and GLP-1 mechanism

Clinical GuideInsulin SensitivityMetabolism

Clinical Guide 8 min readJuly 2, 2026

GLP-1 and Insulin Sensitivity: What's Actually Happening in Your Cells

The number on the scale gets the attention. The quieter change is happening one cell at a time — how GLP-1 medicines reopen the cellular door to insulin.

MicrodoseGLPs Research

Read Article

Woman representing GLP-1 and estrogen interaction across different life decades

Clinical GuideEstrogenWomen's Health

Clinical Guide 8 min readJune 30, 2026

GLP-1 and Estrogen: Why Women's Results Look Different at Every Decade

The same molecule. The same dose. And a body that answers to it differently at 30, at 45, and at 60. Here is why.

MicrodoseGLPs Research

Read Article

Food spread from above representing food noise and appetite regulation via dopamine

Clinical GuideDopamineFood Noise

Neuroscience 9 min readJune 29, 2026

The Dopamine Connection: Why GLP-1 Changes How You Think About Food

The medicine works in your stomach. The strangest part of it works in your head. How GLP-1 medicines quiet food noise by dialing down the brain's dopamine driven reward response.

MicrodoseGLPs Research

Read Article

Person in a calm setting representing mental health and mood on GLP-1 therapy

Mood & CognitionAnxietyFocus

Mental Health 10 min readJune 28, 2026

GLP-1 and Mental Health: Emerging Research on Mood, Anxiety, and Focus

The same receptors that quiet hunger sit deep inside the brain regions that govern mood, motivation, and attention. The evidence is mixed — and worth understanding before you start.

MicrodoseGLPs Research

Read Article

Clinical laboratory setting representing head-to-head comparison of semaglutide and tirzepatide

Clinical GuideSemaglutideTirzepatide

Clinical Guide 9 min readJune 27, 2026

Semaglutide vs. Tirzepatide: Which GLP-1 Is Right for Your Goals

Two molecules, two mechanisms, one decision. Here is what the head to head data actually says, and how to match the drug to your goal.

MicrodoseGLPs Research

Read Article

Athletic person representing muscle preservation during GLP-1 weight loss with peptide support

PeptidesMuscleBody Composition

Peptides 9 min readJune 26, 2026

How Peptides Preserve Muscle During Weight Loss

Up to 40% of weight lost on GLP-1s can come from lean tissue. Here is how CJC-1295, Ipamorelin, and Tesamorelin stack against that problem.

MicrodoseGLPs Research

Read Article

Person lifting weights in a gym representing muscle retention during GLP-1 weight loss

Body CompositionLean MassProtein

Body Composition 8 min readJune 25, 2026

GLP-1 and Muscle Retention: How to Protect Lean Mass While Losing Fat

Most weight lost on a GLP-1 is a blend of fat, water, and muscle. Here is how protein, resistance training, and a slower loss rate change that ratio.

MicrodoseGLPs Research

Read Article

Medical syringe and vial representing precision GLP-1 microdosing

MicrodosingGLP-1Dosing Strategy

Protocols 8 min readJune 24, 2026

What Is Microdosing GLP-1, and Why People Are Choosing It Over Full Doses

A growing number of people are deliberately staying below the standard maintenance dose. Here is what microdosing means, why people choose it, and what the tradeoff actually looks like.

MicrodoseGLPs Research

Read Article

Person wearing a health tracking wearable representing progress monitoring on a GLP-1 microdose protocol

Practical GuideTrackingProtocol Data

Metrics That Matter 8 min readJune 23, 2026

How to Track Progress on a Microdose GLP-1 Protocol

The scale moves last. Here is what tends to move first — a guide to the five metrics that reveal progress before the bathroom scale does.

MicrodoseGLPs Research

Read Article

Person with hands over abdomen surrounded by botanical illustrations and beneficial bacteria in golden light

10 ReasonsGut HealthMicrobiome

Digestive Rhythm + Microbiome 7 min read

10 Reasons Microdosing GLP-1 May Support Gut Health

Your gut is a signaling system. GLP-1 was born inside it. Ten mechanisms by which microdosing GLP-1 may support gut health, digestive rhythm, and the microbiome.

MicrodoseGLPs Research

Read Article

Translucent human head showing illuminated neural pathways with labeled brain regions

Neuroscience Deep DiveDopamineReward System

Neuroscience + Reward Circuits 7 min read

What GLP-1 Receptors Are Actually Doing in Your Brain

This is not a hunger story. It is a brain story. GLP-1 medications interact with your dopamine circuits, hypothalamus, and vagal nerve in ways that change how desire, reward, and satisfaction feel.

Metabolic Intelligence

Read Article

Person meditating in a bright space with neural network light patterns suggesting brain connectivity

Brain HealthNeuroplasticityMood

Mental Health + Neuroplasticity 22 min read

Microdose GLP-1 and Mental Health: Anxiety, Depression, and Neuroplasticity

Clinical evidence on how microdose GLP-1 protocols improve mental health outcomes through neuroinflammation reduction, BDNF elevation, gut-brain axis modulation, and enhanced neuroplasticity.

MicrodoseGLPs Research

Read Article

Confident fit woman in her late 40s performing a dumbbell press in a bright boutique gym

Women Over 40Bone HealthHormones

Women's Health + Bone Density 20 min read

Microdose GLP-1 for Women Over 40: Hormones, Bone Density, and Metabolic Optimization

Clinical evidence on why post-menopausal women benefit most from microdose protocols, covering bone density preservation, hormonal interactions, lean mass retention, and menopausal symptom improvement.

MicrodoseGLPs Research

Read Article

Person peacefully sleeping in a serene bedroom at dawn with a precision medicine vial on the nightstand

Sleep ScienceCircadian Rhythm

Sleep + Circadian Health 18 min read

GLP-1s and Sleep Quality: How Microdosing Protects Your Circadian Rhythm

Clinical evidence showing how full dose GLP-1 therapy suppresses melatonin by 37%, reduces deep sleep by 33%, and elevates nighttime cortisol, while microdose protocols preserve and enhance sleep architecture.

MicrodoseGLPs Research

Read Article

Couple contemplating their Ozempic injection pen beside an untouched plate of food in a modern kitchen

10 ReasonsSide Effects

Side Effects + Patient Experience 22 min read

The Side Effects of Ozempic and Why Patients Are Quietly Switching to Microdose Protocols

10 reasons patients are abandoning full dose Ozempic for microdose GLP-1 protocols, from severe nausea and muscle loss to gastroparesis and hair thinning. Clinical data shows 44% nausea drops to just 10% at microdose levels.

MicrodoseGLPs Research

Read Article

Morning kitchen counter with empty plate, water glass, and precision medicine vial in golden hour light

10 ReasonsLifestyle Synergy

Lifestyle Synergy 20 min read

10 Reasons Microdose GLP-1 Pairs Better With Intermittent Fasting

Why the combination of low dose GLP-1 therapy and structured fasting windows produces 95% peak fat oxidation, 70% insulin sensitivity gains, and 78% twelve month adherence at one third the medication cost.

MicrodoseGLPs Research

Read Article

Healthy couple in their 60s walking on a sunlit coastal path at golden hour

10 ReasonsSafety + Longevity

Safety + Longevity 22 min read

10 Reasons Microdose GLP-1 Is Safer for Long Term Use Than Standard Protocols

Why lower cumulative organ exposure, preserved metabolic function, and 75% three year adherence make microdosing the only GLP-1 strategy designed for decades of safe, sustainable use.

MicrodoseGLPs Research

Read Article

Fit man in his 50s performing a barbell squat in a modern gym

10 ReasonsOver 50

Strength + Aging 20 min read

10 Reasons Why Microdose Beats Full-Dose For Anyone Over 50 Who Lifts

Why standard GLP-1 doses destroy the muscle you spent decades building, and how microdosing preserves 93% of lean mass, 92% of strength, and actually improves bone density in lifters over 50.

MicrodoseGLPs Research

Read Article

Diverse group of healthy adults in modern wellness space

Featured10 Reasons

Metabolic Health 18 min read

10 Reasons Why Microdosing GLP-1s Is the Future of Metabolic Health

From 73% fewer side effects and $10K+ annual savings to better weight maintenance and longevity benefits. A comprehensive, evidence based breakdown of why low dose GLP-1 protocols are gaining momentum.

MicrodoseGLPs Research

Read Article

Gastroenterology

Nausea
Vomiting

Gastroenterology 14 min read

GLP-1 Therapy and Gut Health: Microbiome, Side Effects, and Optimization

How GLP-1 receptor agonists reshape the gut microbiome, why GI side effects occur and resolve over time, and evidence based strategies for optimizing digestive health during semaglutide or tirzepatide therapy. Includes 6 interactive visualizations.

MicrodoseGLPs Research

Read Article

Exercise Science

Lean Mass Retained
Fat Loss Efficiency

Exercise Science 16 min read

Exercise and Muscle Preservation on GLP-1 Therapy

Why resistance training is essential during GLP-1 therapy, how to prevent the 25% lean mass loss seen in sedentary users, and the optimal exercise and protein protocol backed by STEP, S-LiTE, and LEAN-PREP trial data. Includes 6 interactive visualizations.

MicrodoseGLPs Research

Read Article

Cardiovascular Science

Cardiovascular Science 14 min read

GLP-1 Receptor Agonists and Cardiovascular Health

How GLP-1 receptor agonists reduce major adverse cardiovascular events by up to 26%, protect against heart failure, and deliver anti inflammatory benefits that extend far beyond weight loss. Featuring data from the SELECT, SUSTAIN-6, and STEP-HFpEF trials with 6 interactive visualizations.

MicrodoseGLPs Research

Read Article

Data-Driven Analysis

Standard RDA
Optimal on GLP-1

Nutrition Science 12 min read

Protein Requirements on a GLP-1 Protocol

Why standard protein recommendations fall short during GLP-1 microdosing, and the data driven approach to preserving lean mass while optimizing metabolic outcomes. Includes 6 interactive data visualizations.

MicrodoseGLPs Research

Read Article

Comprehensive Guide

Microdose
Full Dose

Microdosing Protocol 15 min read

The Complete Guide to Microdosing GLP-1s: Lower Doses, Better Outcomes

An evidence based analysis of GLP-1 microdosing protocols comparing side effects, body composition outcomes, and metabolic markers versus standard dosing. Includes 6 interactive data visualizations.

MicrodoseGLPs Research

Read Article